Compare Lamb Weston Holdings Inc (LW) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Repligen Corporation Common Stock — how do they compare? Lamb Weston Holdings Inc trades at $53.22 (market cap $7.16B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 2.93% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Repligen Corporation Common Stock for 0 Days on average.
| LW | RGEN | |
|---|---|---|
Market Cap | $7.16B | $11.14B |
Volume | 2,766,229 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $194.57 |
52-Week Low | $38.48 | $102.87 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $10.95B | $11.02B |
Dividend Yield | 2.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $53.02, up 5.66% today, near the consensus price target of $53.71. The stock shows bullish technical signals with strong moving averages and recent earnings beats. Revenue reached $6.45B in 2025, though net income margin compressed to 3.85%. The company maintains a solid balance sheet with $70.70M cash and ongoing dividend payments of $0.38 per share.
Outlook remains mixed; analyst consensus leans Hold (63%) with potential upside to $58.00. Key risks include margin pressure from high debt and volatile earnings. Positive sentiment from cost-saving initiatives supports recovery, but investor confidence hinges on sustained profitability improvements amid competitive pressures.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
